Innovation Pharmaceuticals Inc (IPIX)

[slcimmuno]

Good visual, good reminder.
Here is the full Polymedix Brilacidin fact sheet based on the ph 2a, with some early info on B-Om listed too

http://files.shareholder.com/downloads/ABEA-4ITCYZ/1997024712x0x611205/FEA66C67-D02F-4FF2-B230-AA711F46ED7F/PMX-30063_Antibiotic_Fact_Sheet_Nov_2012_.pdf

What we know: B is safer than Dapto (no attributable SAEs -- unlike what ph 2a showed due to poor data followup) and as effective as Dapto across all 3 arms (new info as Big K pointed out). Plus the M-ITT MRSA data is icing on cake. A good CDC resource on MRSA:
http://www.cdc.gov/mrsa/

Below a fuller reminder of what Brilacidin was/is up against in Daptomcin. When full results are released (the mining of the PK data, thousands of pages Leo mentioned) we'll better be able to compare B vs D, apples to apple.

http://www.medscape.com/viewarticle/827923_6

Found this slide deck (circa 2013 it appears) on ABSSSI and -- note pg 3: TREATMENT FAILURE. That the 23% failure rate of initial antibiotics results in 5.4 days of added LOS, $5285 in addtl inpatient costs, and a 3-fold increase in patient mortality. B's bacteriocity should be much more effective here.

http://www.ashpadvantagemedia.com/id/resources/handout_id_ondemand.pdf